Edition:
India

Agile Therapeutics Inc (AGRX.OQ)

AGRX.OQ on NASDAQ Stock Exchange Global Market

0.58USD
1:30am IST
Change (% chg)

$0.01 (+1.40%)
Prev Close
$0.57
Open
$0.55
Day's High
$0.59
Day's Low
$0.54
Volume
36,506
Avg. Vol
70,645
52-wk High
$5.59
52-wk Low
$0.54

Select another date:

Fri, May 18 2018

Photo

Agile Therapeutics sinks after FDA feedback on contraceptive

Agile Therapeutics Inc's shares sank 75 percent on Friday after the drug developer said it expects to pursue what could be a prolonged appeal against health regulators' issues over its chief experimental product, a contraceptive patch.

UPDATE 2-Agile Therapeutics sinks after FDA feedback on contraceptive

* FDA suggests additional study of contraceptive may be needed

Agile Therapeutics exploring funding options after FDA meeting

May 18 Agile Therapeutics Inc said on Friday it was looking for ways to fund operations after a meeting with the U.S. health regulator raised the possibility of a new clinical trial to test its stick-on contraceptive patch, Twirla.

BRIEF-Agile Therapeutics Reports Q1 Loss Per Share $0.20

* AGILE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Agile Therapeutics Reports Q4 Loss Per Share $0.18

* AGILE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Perceptive Advisors Reports 9.9 Pct Passive Stake In Agile Therapeutics

* Perceptive Advisors LLC Reports A 9.9 Pct Passive Stake In Agile Therapeutics Inc As Of Dec 22, 2017 - SEC Filing Source text: (http://bit.ly/2FlgqN8) Further company coverage:

FDA rejects Agile's contraceptive patch, shares plunge

Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its contraceptive patch for the second time, sending the drug developer's shares down about 50 percent.

FDA declines to approve Agile's contraceptive patch

Dec 22 Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve the company's contraceptive patch, citing deficiencies related to its adhesion test methods.

BRIEF-Agile Therapeutics Gets Response Letter From FDA For Pregnancy Prevention Drug Twirla

* AGILE THERAPEUTICS, INC. RECEIVES A COMPLETE RESPONSE LETTER FROM THE FDA FOR TWIRLA® (AG200-15) FOR THE PREVENTION OF PREGNANCY

Select another date: